The Purpose of a randomized, double-blind, placebo-controlled, single-dose, dose-escalation clinical trial is to explore investigate the safety, tolerability, pharmacokinetics, and food effect of PMK-S005 after oral administration in healthy male volunteers.

Inclusion Criteria:

• Male 20 year ≤ age ≤ 40 year.
• Weight ≥ 55kg, IBW ±20%.
• Patients with normal hematology, biochemistry, urinary result.
• Patients who have not congenital or chronic disease.
• Provision of written informed consent voluntarily.

Exclusion Criteria:

• Patients having known hypersensitivity to any component of the study drug.
• Patients with a history of abnormal digestive organ, kidney, respiratory, neuroendocrine, cardiovascular, hemato-oncology, urinary, muscloskeletal, immune, the nose and ears, psychiatry, stomach system.
• Patients with any gastrointestinal disorders.
• Systolic blood pressure ≥ 150 or ≤ 90 mmHg, Diasolic blood pressure ≥ 95 or ≤ 50 mmHg.
• Drug abuser, alcoholic.
• Patients taking ETC medication within 14 days, OTC within 7 days.
• Patients taking other investigational product within 60 days prior to the participation in the study.